遺伝子編集市場：用途別、技術別、場所別、業界別、製品別 - エグゼクティブコンサルタントガイド付き（2025年～2029年）

遺伝子編集は力強さを増しています。CRISPRや同様のツールは、バイオテクノロジーのあらゆる分野で新たな用途を見出しています。CRISPRは、生きたヒト細胞の遺伝子を改変することによって、医療への応用から始まっています。不治の病はすでに治癒しています。さらに多くの病気が進行中です。急成長路線が加速し、複数の産業で新たな用途が開発されています。技術の飛躍的進歩のたびに、新たな機会が生まれています。

当レポートは、世界の遺伝子編集市場について調査し、市場の概要とともに、用途別、技術別、タイプ別、業界別、製品別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

• 調査手法
• 遺伝子編集とは何か
• CRISPRの例
• 染色体、遺伝子、エピジェネティクス
• 市場の定義
• 視点：ヘルスケア費支出

第3章 市場構造

• 市場構造治療薬
  • 研究開発（R&D）企業
  • バイオテクノロジー企業
  • ジェネリック医薬品メーカー
  • 大手製薬会社
  • CRO
  • CMO
  • 専門医薬品会社
  • 医薬品販売業者
  • 小売薬局
  • 卸売業者
  • オンライン薬局
  • 医療技術企業
  • 薬局給付管理者（PBM）
  • 臨床検査室
  • 医療機器メーカー
  • 規制機関
• 市場構造診断
  • 学術研究機関
  • 診断試験開発者
  • 計測機器サプライヤー
  • 薬品・試薬メーカー
  • 病理サプライヤー
  • 独立系臨床検査室
  • 公共の国立/地域研究所
  • 病院検査室
  • 臨床検査室
  • 監査機関
  • 認証機関

第4章 市場動向

• 成長促進要因
• 成長阻害要因

第5章 遺伝子編集の最近の動向

第6章 主要企業

• 10x Genomics, Inc.
• 4D Molecular Therapeutics
• Abeona Therapeutics
• Acrigen Biosciences
• Adarx Pharmaceuticals
• Adverum Biotechnologies
• Affini-T Therapeutics
• Agilent
• Arbor Biotechnologies
• Arcturus Therapeutics
• Axxam
• Beam Therapeutics
• Beckman Coulter Diagnostics（Danaher）
• Becton, Dickinson and Company
• Binx Health
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc.
• Bluebird Bio
• Caribou Biosciences
• Cell Microsystems
• Cellenion（BICO）
• Century Therapeutics
• Chroma Medicine
• Creative Biogene
• Crispr Therapeutics
• Editas Medicine
• ERS Genomics
• FASMAC
• Genscript Biotech
• Illumina
• Inscripta
• Intellia Therapeutics
• J&J Innovative Medicine
• Locus Biosciences
• Mammoth Biosciences
• Metagenomi
• Myllia Biotechnology
• Namocell
• NRGene
• Poseida Therapeutics
• Precision Biosciences
• Prime Medicine
• Proof Diagnostics
• Regeneron Pharmaceuticals
• Revvity
• Roche Diagnostics
• Sherlock Biosciences
• Thermo Fisher Scientific
• Twist Bioscience
• Verve Therapeutics
• Vivlion
• Wave Life Science

第7章 世界の遺伝子編集市場

• 国別世界市場概要
• 用途別世界市場- 概要
• 技術別世界市場- 概要
• タイプ別世界市場- 概要
• 業界別世界市場- 概要
• 製品別世界市場- 概要

第8章 世界の遺伝子編集市場- 用途別

• 細胞株
• 植物
• 動物
• 細胞療法
• 遺伝子治療
• 診断
• 研究
• その他

第9章 世界の遺伝子編集市場- 技術別

• CRISPR
• TALEN
• ZFN
• メガヌクレアーゼ
• その他

第10章 世界の遺伝子編集市場- 場所別

• 生体内
• 生体外
• 体外

第11章 世界の遺伝子編集市場- 業界別

• 製薬
• 臨床
• 学術
• 受託
• その他

第12章 世界の遺伝子編集市場- 製品別

• 機器
• 細胞
• 試薬
• その他

第13章 付録

Table of Tables

• Table 1: The Base Pairs
• Table 2: The Base Pairs
• Table 3: Market Players by Type
• Table 4: Market Players by Type
• Table 5: The Factors Driving Growth
• Table 6: Factors Limiting Growth
• Table 7: Global Market by Region
• Table 8: Global Market by Application
• Table 9: Global Market by Technology
• Table 10: Global Market by Type
• Table 11: Global Market by Industry
• Table 12: Global Market by Product
• Table 13: Cell Line by Country
• Table 14: Plant by Country
• Table 15: Animal by Country
• Table 16: Cell Therapy by Country
• Table 17: Gene Therapy by Country
• Table 18: Diagnostics by Country
• Table 19: Research by Country
• Table 20: Other Application by Country
• Table 21: Crispr by Country
• Table 22: Talens by Country
• Table 23: ZFN by Country
• Table 24: Meganuclease by Country
• Table 25: Other Technology by Country
• Table 26: In Vivo by Country
• Table 27: Ex Vivo by Country
• Table 28: In Vitro by Country
• Table 29: Pharma by Country
• Table 30: Clinical by Country
• Table 31: Academic by Country
• Table 32: Contract by Country
• Table 33: Other Industry by Country
• Table 34: Instruments by Country
• Table 35: Cells by Country
• Table 36: Reagents by Country
• Table 37: Other Product by Country
• Table 38: Clinical Lab Fee Schedule
• Table 39: The Most Common Assays
• Table 40: Largest Revenue Assays
• Table 41: List of Global Sequencing Locations

Table of Figures

• Figure 1: DNA Strands and Chromosomes
• Figure 2: Karyogram of Human Chromosomes
• Figure 3: Size of Various Genomes
• Figure 4: Global Per Capita Healthcare Spending
• Figure 5: The Road to Therapeutics
• Figure 6: The Road to Diagnostics
• Figure 7: Cost To Sequence a Human Genome
• Figure 8: Base Year Country Market Share Chart
• Figure 9: Global Market by Application - Base vs. Final Year
• Figure 10: Global Market by Application Base Year
• Figure 11: Global Market by Application Final Year
• Figure 12: Application Type Share by Year
• Figure 13: by Application Segment Growth
• Figure 14: by Technology - Base vs. Final Year
• Figure 15: by Technology Market Base Year
• Figure 16: by Technology Market Final Year
• Figure 17: by Technology Share by Year
• Figure 18: by Technology Segment Growth
• Figure 19: by Type - Base vs. Final Year
• Figure 20: by Type Market Base Year
• Figure 21: by Type Market Final Year
• Figure 22: by Type Share by Year
• Figure 23: by Type Segment Growth
• Figure 24: by Industry - Base vs. Final Year
• Figure 25: by Industry Market Base Year
• Figure 26: by Industry Market Final Year
• Figure 27: by Industry Share by Year
• Figure 28: by Industry Segment Growth
• Figure 29: by Product - Base vs. Final Year
• Figure 30: by Product Market Base Year
• Figure 31: by Product Market Final Year
• Figure 32: by Product Share by Year
• Figure 33: by Product Segment Growth
• Figure 34: Cell Line Growth
• Figure 35: Plant Growth
• Figure 36: Animal Growth
• Figure 37: Cell Therapy Growth
• Figure 38: Gene Therapy Growth
• Figure 39: Diagnostics Growth
• Figure 40: Research Growth
• Figure 41: Other Application Growth
• Figure 42: Crispr Growth
• Figure 43: Talens Growth
• Figure 44: ZFN Growth
• Figure 45: Meganuclease Growth
• Figure 46: Other Organism Growth
• Figure 47: In Vivo Growth
• Figure 48: Ex Vivo Growth
• Figure 49: In Vitro Growth
• Figure 50: Pharma Growth
• Figure 51: Clinical Growth
• Figure 52: Academic Growth
• Figure 53: Contract Growth
• Figure 54: Other Industry Growth
• Figure 55: Instruments Growth
• Figure 56: Cells Growth
• Figure 57: Reagents Growth
• Figure 58: Other Product Growth

OVERVIEW:

Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way. A fast growth path is accelerating. New applications are developing in multiple industries. New opportunities are arising with every technological breakthrough. Understand the various opportunities. Find out what is expected in the near term and the long term. Get a handle on realistic growth expectations. Our research makes you the expert in your organization.

All report data is available in Excel format on request.

Table of Contents

1. Market Guides

• 1.1. Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

• 2.1. Methodology
  • 2.1.1. Methodology
  • 2.1.2. Sources
  • 2.1.3. Authors
• 2.2. What is Gene Editing?
• 2.3. The CRISPR Example
  • 2.3.1. What is CRISPR?
  • 2.3.2. The CRISPR Family
• 2.4. Chromosomes, Genes and Epigenetics
  • 2.4.1. Chromosomes
  • 2.4.2. Genes
  • 2.4.3. Epigenetics
• 2.5. Market Definition
  • 2.5.1. Revenue Market Size
• 2.6. Perspective: Healthcare Spending
  • 2.6.1. Global Healthcare Spending
  • 2.6.2. Spending on Healthcare and Pharmaceuticals
  • 2.6.3. Spending on Diagnostics
  • 2.6.4. Important Role of Insurance for Medical Services

3. Market Structure

• 3.1. Market Structure Therapeutics
  • 3.1.1. Research and Development (R&D) Companies
  • 3.1.2. Biotechnology Companies
  • 3.1.3. Generic Drug Manufacturers
  • 3.1.4. Big Pharmaceuticals
  • 3.1.5. Contract Research Organizations (CROs)
  • 3.1.6. Contract Manufacturing Organizations (CMOs)
  • 3.1.7. Specialty Pharmaceutical Companies
  • 3.1.8. Pharmaceutical Distributors
  • 3.1.9. Retail Pharmacies
  • 3.1.10. Wholesalers
  • 3.1.11. Online Pharmacies
  • 3.1.12. Health Technology Companies
  • 3.1.13. Pharmacy Benefit Managers (PBMs)
  • 3.1.14. Clinical Laboratories
  • 3.1.15. Medical Device Companies
  • 3.1.16. Regulatory Bodies
• 3.2. Market Structure Diagnostics
  • 3.2.1. Academic Research Lab
  • 3.2.2. Diagnostic Test Developer
  • 3.2.3. Instrumentation Supplier
  • 3.2.4. Chemical/Reagent Supplier
  • 3.2.5. Pathology Supplier
  • 3.2.6. Independent Clinical Laboratory
  • 3.2.7. Public National/regional Laboratory
  • 3.2.8. Hospital Laboratory
  • 3.2.9. Physicians Office Lab (POLS)
  • 3.2.10. Audit Body
  • 3.2.11. Certification Body

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Cell Therapy
  • 4.1.2. Gene Therapy
  • 4.1.3. The New Agriculture
  • 4.1.4. Genetics and Cell Metabolism
• 4.2. Factors Limiting Growth
  • 4.2.1. The Cost Curve
  • 4.2.2. Time and Trials
  • 4.2.3. The Price Barrier

5. Recent Developments in Gene Editing

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. CRISPR tool allows for remote-controlled gene-editing
• 5.3. CRISPR Making Sweeter Tomatoes
• 5.4. Researchers Create gene-edited prawns
• 5.5. Gene Editing Corrects Cystic Fibrosis
• 5.6. CRISPR gene editing to change healthcare?
• 5.7. CrisprBits Collaborates With MolBio Diagnostics
• 5.8. Sherlock Bioscience to Launch Free AI-Based Operating System
• 5.9. Sherlock Biosciences to Acquire Sense Biodetection
• 5.10. CRISPR Enzyme Discovery Opens New Applications
• 5.11. Sherlock Biosciences Adds Ambient Amplification to Toolkit
• 5.12. Rice University Adapts CRISPR Enzyme
• 5.13. Princeton Group Develops Cas13 Assay for Point-of-Care Use
• 5.14. Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System
• 5.15. Sherlock Biosciences Raises $80M
• 5.16. Broad Institute Considers CRISPR Respiratory Panels to Replace PCR
• 5.17. Medix Biochemica Acquires MyPols Biotec
• 5.18. Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA
• 5.19. Genome Diagnostics Makes Euro-1M Investment in Scope Biosciences
• 5.20. CRISPR Test Could be used for Asymptomatic Screening
• 5.21. Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test
• 5.22. Pandemic Accelerates Development of CRISPR Diagnostics
• 5.23. ERS Genomics Licenses CRISPR Patents to Vivlion
• 5.24. Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test
• 5.25. ERS Genomics, FASMAC to Commercialize CRISPR-Cas9
• 5.26. The Nobel Prize in Chemistry 2020 - CRISPR Wins

6. Key Companies

• 6.1 10x Genomics, Inc.
• 6.2 4D Molecular Therapeutics
• 6.3. Abeona Therapeutics
• 6.4. Acrigen Biosciences
• 6.5. Adarx Pharmaceuticals
• 6.6. Adverum Biotechnologies
• 6.7. Affini-T Therapeutics
• 6.8. Agilent
• 6.9. Arbor Biotechnologies
• 6.10. Arcturus Therapeutics
• 6.11. Axxam
• 6.12. Beam Therapeutics
• 6.13. Beckman Coulter Diagnostics (Danaher)
• 6.14. Becton, Dickinson and Company
• 6.15. Binx Health
• 6.16. bioMerieux Diagnostics
• 6.17. Bio-Rad Laboratories, Inc.
• 6.18. Bluebird Bio
• 6.19. Caribou Biosciences
• 6.20. Cell Microsystems
• 6.21. Cellenion (BICO)
• 6.22. Century Therapeutics
• 6.23. Chroma Medicine
• 6.24. Creative Biogene
• 6.25. Crispr Therapeutics
• 6.26. Editas Medicine
• 6.27. ERS Genomics
• 6.28. FASMAC
• 6.29. Genscript Biotech
• 6.30. Illumina
• 6.31. Inscripta
• 6.32. Intellia Therapeutics
• 6.33. J&J Innovative Medicine
• 6.34. Locus Biosciences
• 6.35. Mammoth Biosciences
• 6.36. Metagenomi
• 6.37. Myllia Biotechnology
• 6.38. Namocell
• 6.39. NRGene
• 6.40. Poseida Therapeutics
• 6.41. Precision Biosciences
• 6.42. Prime Medicine
• 6.43. Proof Diagnostics
• 6.44. Regeneron Pharmaceuticals
• 6.45. Revvity
• 6.46. Roche Diagnostics
• 6.47. Sherlock Biosciences
• 6.48. Thermo Fisher Scientific
• 6.49. Twist Bioscience
• 6.50. Verve Therapeutics
• 6.51. Vivlion
• 6.52. Wave Life Science

7. The Global Market for Gene Editing

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Application - Overview
  • 7.2.1. Table - Global Market by Application
  • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Application - Base Year
  • 7.2.4. Chart - Global Market by Application - Final Year
  • 7.2.5. Chart - Global Market by Application - Share by Year
  • 7.2.6. Chart - Global Market by Application - Segment Growth
• 7.3. Global Market Technology - Overview
  • 7.3.1. Table - Global Market by Technology
  • 7.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Technology - Base Year
  • 7.3.4. Chart - Global Market by Technology - Final Year
  • 7.3.5. Chart - Global Market by Technology - Share by Year
  • 7.3.6. Chart - Global Market by Technology - Segment Growth
• 7.4. Global Market Type - Overview
  • 7.4.1. Table - Global Market by Type
  • 7.4.2. Chart - Global Market by Type - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Type - Base Year
  • 7.4.4. Chart - Global Market by Type - Final Year
  • 7.4.5. Chart - Global Market by Type - Share by Year
  • 7.4.6. Chart - Global Market by Type - Segment Growth
• 7.5. Global Market Industry - Overview
  • 7.5.1. Table - Global Market by Industry
  • 7.5.2. Chart - Global Market by Industry - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market by Industry - Base Year
  • 7.5.4. Chart - Global Market by Industry - Final Year
  • 7.5.5. Chart - Global Market by Industry - Share by Year
  • 7.5.6. Chart - Global Market by Industry - Segment Growth
• 7.6. Global Market Product - Overview
  • 7.6.1. Table - Global Market by Product
  • 7.6.2. Chart - Global Market by Product - Base/Final Year Comparison
  • 7.6.3. Chart - Global Market by Product - Base Year
  • 7.6.4. Chart - Global Market by Product - Final Year
  • 7.6.5. Chart - Global Market by Product - Share by Year
  • 7.6.6. Chart - Global Market by Product - Segment Growth

8. Gene Editing Markets - By Application

• 8.1. Cell Line
  • 8.1.1. Table Cell Line - by Country
  • 8.1.2. Chart - Cell Line Growth
• 8.2. Plant
  • 8.2.1. Table Plant - by Country
  • 8.2.2. Chart - Plant Growth
• 8.3. Animal
  • 8.3.1. Table Animal - by Country
  • 8.3.2. Chart - Animal Growth
• 8.4. Celll Therapy
  • 8.4.1. Table Cell Therapy - by Country
  • 8.4.2. Chart - Cell Therapy Growth
• 8.5. Gene Therapy
  • 8.5.1. Table Gene Therapy - by Country
  • 8.5.2. Chart - Gene Therapy Growth
• 8.6. Diagnostics
  • 8.6.1. Table Diagnostics - by Country
  • 8.6.2. Chart - Diagnostics Growth
• 8.7. Research
  • 8.7.1. Table Research - by Country
  • 8.7.2. Chart - Research Growth
• 8.8. Other Application
  • 8.8.1. Table Other Application - by Country
  • 8.8.2. Chart - Other Application Growth

9. Global Gene Editing Markets - by Technology

• 9.1. Crispr
  • 9.1.1. Table Crispr - by Country
  • 9.1.2. Chart - Crispr Growth
• 9.2. Talens
  • 9.2.1. Table Talens - by Country
  • 9.2.2. Chart - Talens Growth
• 9.3. ZFN
  • 9.3.1. Table ZFN - by Country
  • 9.3.2. Chart - ZFN Growth
• 9.4. Meganuclease
  • 9.4.1. Table Meganuclease - by Country
  • 9.4.2. Chart - Meganuclease Growth
• 9.5. Other Technology
  • 9.5.1. Table Other Technology - by Country
  • 9.5.2. Chart - Other Technology Growth

10. Gene Editing Markets - by Place

• 10.1. In Vivo
  • 10.1.1. Table In Vivo - by Country
  • 10.1.2. Chart - In Vivo Growth
• 10.2. Ex Vivo
  • 10.2.1. Table Ex Vivo - by Country
  • 10.2.2. Chart - Ex Vivo Growth
• 10.3. In Vitro
  • 10.3.1. Table In Vitro - by Country
  • 10.3.2. Chart - In Vitro Growth

11. Gene Editing Markets - by Industry

• 11.1. Pharma
  • 11.1.1. Table Pharma - by Country
  • 11.1.2. Chart - Pharma Growth
• 11.2. Clinical
  • 11.2.1. Table Clinical - by Country
  • 11.2.2. Chart - Clinical Growth
• 11.3. Academic
  • 11.3.1. Table Academic - by Country
  • 11.3.2. Chart - Academic Growth
• 11.4. Contract
  • 11.4.1. Table Contract - by Country
  • 11.4.2. Chart - Contract Growth
• 11.5. Other Industry
  • 11.5.1. Table Other Industry - by Country
  • 11.5.2. Chart - Other Industry Growth

12. Global Gene Editing Markets - by Product

• 12.1. Instruments
  • 12.1.1. Table Instruments - by Country
  • 12.1.2. Chart - Instruments Growth
• 12.2. Cells
  • 12.2.1. Table Cells - by Country
  • 12.2.2. Chart - Cells Growth
• 12.3. Reagents
  • 12.3.1. Table Reagents - by Country
  • 12.3.2. Chart - Reagents Growth
• 12.4. Other Product
  • 12.4.1. Table Other Product - by Country
  • 12.4.2. Chart - Other Product Growth

13. Appendices

• 13.1. United States Medicare System: laboratory Fees Schedule
• 13.2. The Most Used IVD Assays
• 13.3. The Highest Grossing Assays
• 13.4. The Whole Genome Sequence of SARS-CoV-2
• 13.5. Global Listing of Sequencing Establishments - Location & Contacts